Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain
Unknown statusNot applicableNCT04838925
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to develop and test the feasibility of a commercially-ready mobile neurofeedback app for individuals with chronic pain. Thirty (30) participants who are prescribed opioids for chronic pain will use the new mobile neurofeedback app and an EEG headset for 10 minutes at a time, 4 times a week for 12 weeks and provide feedback about using the app.
Study details
- Official title
- Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain
- Conditions
- Interventions
- Device: Mobile Neurofeedback App
- Sponsor
- CrossComm, Inc.
- Collaborators
- Duke University; National Institute on Drug Abuse (NIDA)
- Start date
- 2022-06-22
- Primary completion
- 2023-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Reports chronic pain (≥4 on 0-10 Numeric Rating Scale (NRS) on most days during the past 3 months) * Prescribed opioids for pain management Exclusion Criteria: * History of seizures * Plans to have pain-related surgery in the next 3 months * Has an implanted medical device that could experience interference during EEG, such as a spinal cord stimulator or pacemaker
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04838925